Drug Approval | April 27, 2023
Ipca Laboratories gets 3 observations for Piparia, Silvassa unit
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
The business and product range of Ipca and that of Unichem complements each others business and product range
A special technique of jet injection is used to make vaccination almost painless and totally needleless.
Bridging the gap between histopathology and molecular pathology
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Subscribe To Our Newsletter & Stay Updated
